Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001731122-25-000205
Filing Date
2025-02-12
Accepted
2025-02-12 09:06:26
Documents
46
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q e6338_10-q.htm   iXBRL 10-Q 530486
2 EXHIBIT 31.1 e6338_ex31-1.htm EX-31.1 7921
3 EXHIBIT 31.2 e6338_ex31-2.htm EX-31.2 7921
4 EXHIBIT 32.1 e6338_ex32-1.htm EX-32.1 5931
5 GRAPHIC image_001.jpg GRAPHIC 28868
6 GRAPHIC image_002.jpg GRAPHIC 28350
  Complete submission text file 0001731122-25-000205.txt   2806199

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE avxl-20241231.xsd EX-101.SCH 23944
8 XBRL CALCULATION FILE avxl-20241231_cal.xml EX-101.CAL 25040
9 XBRL DEFINITION FILE avxl-20241231_def.xml EX-101.DEF 70193
10 XBRL LABEL FILE avxl-20241231_lab.xml EX-101.LAB 188209
11 XBRL PRESENTATION FILE avxl-20241231_pre.xml EX-101.PRE 142264
48 EXTRACTED XBRL INSTANCE DOCUMENT e6338_10-q_htm.xml XML 325559
Mailing Address 630 5TH AVENUE 20TH FLOOR NEW YORK NY 10111
Business Address 630 5TH AVENUE 20TH FLOOR NEW YORK NY 10111 844-689-3939
ANAVEX LIFE SCIENCES CORP. (Filer) CIK: 0001314052 (see all company filings)

EIN.: 980608404 | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 001-37606 | Film No.: 25612260
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)